Reapplix
  • About Reapplix
    • About Reapplix
    • About 3C Patch®
    • Executive Management
    • Board of Directors
    • Investors
  • News and press
  • Conferences
  • Contact
Select Page

Large international randomized controlled trial on LeucoPatch started 2013

Oct 5, 2013

A study of more than 250 diabetic foot ulcer patients will be initiated in cooperation with principal investigators Dr. Löndahl, Dr. Game, Prof. Jeffcoate and Dr. Tarnow at several multidisciplinary team based clinical sites in UK, Denmark and Sweden.
← Scandinavian multicenter study of LeucoPatch presentented at EWMA 2013 The large randomized clinical trial of LeucoPatch speeds up →

RECENT POSTS

  • PRESS RELEASE: REAPPLIX RECEIVES CODING AND REIMBURSEMENT DETAILS FOR 3C PATCH® IN THE US – ALL OBSTACLES REMOVED FOR COMMERCIAL EXECUTION 06/10/2021
  • Press Release: Former Urgo Medical Exec Kira Rupprecht Joins Reapplix as Chief Executive Officer 03/05/2021
  • PRESS RELEASE: A FINAL MEDICARE NATIONAL COVERAGE DETERMINATION HAS BEEN PUBLISHED ENABLING SUSTAINABLE US REIMBURSEMENT FOR REAPPLIX’s 3C PATCH® 21/04/2021
  • PRESS RELEASE: REAPPLIX ANNOUNCES APPOINTMENT OF RICHARD TWOMEY TO BOARD OF DIRECTORS 20/10/2020
  • PRESS RELEASE: REAPPLIX RECEIVES NEW REIMBURSEMENT CODING AND COMPLETES USD 22.6M EQUITY FINANCING TO DRIVE US COMMERCIALIZATION 14/07/2020

REAPPLIX INC / US

+1 866 327 2824
Mail to Reapplix US

VISIT OUR PRODUCT SITE 3CPATCH.COM

REAPPLIX A/S HQ / EUROPE

+45 88 16 80 66
Mail to Reapplix Europe

© 2022 Reapplix A/S. All Rights Reserved. 3C Patch® and 3C Patch System® are registered trademarks of Reapplix A/S. For full safety information, please reference the 3C Patch® Instructions for Use. Privacy Policy.
X